These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 20960029)
1. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Paz-Ares L; López-Pousa A; Poveda A; Balañá C; Ciruelos E; Bellmunt J; del Muro JG; Provencio M; Casado A; Rivera-Herrero F; Izquierdo MA; Nieto A; Tanović A; Cortes-Funes H; Buesa JM Invest New Drugs; 2012 Apr; 30(2):729-40. PubMed ID: 20960029 [TBL] [Abstract][Full Text] [Related]
2. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558 [TBL] [Abstract][Full Text] [Related]
3. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506 [TBL] [Abstract][Full Text] [Related]
4. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671 [TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Chu Q; Mita A; Forouzesh B; Tolcher AW; Schwartz G; Nieto A; Soto-Matos A; Alfaro V; Lebedinsky C; Rowinsky EK Clin Cancer Res; 2010 May; 16(9):2656-65. PubMed ID: 20406837 [TBL] [Abstract][Full Text] [Related]
6. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Blay JY; von Mehren M; Samuels BL; Fanucchi MP; Ray-Coquard I; Buckley B; Gilles L; Lebedinsky C; Elsayed YA; Le Cesne A Clin Cancer Res; 2008 Oct; 14(20):6656-62. PubMed ID: 18927308 [TBL] [Abstract][Full Text] [Related]
7. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice. Le Cesne A; Reichardt P Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310 [TBL] [Abstract][Full Text] [Related]
8. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Simpson EL; Rafia R; Stevenson MD; Papaioannou D Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. Yovine A; Riofrio M; Blay JY; Brain E; Alexandre J; Kahatt C; Taamma A; Jimeno J; Martin C; Salhi Y; Cvitkovic E; Misset JL J Clin Oncol; 2004 Mar; 22(5):890-9. PubMed ID: 14990645 [TBL] [Abstract][Full Text] [Related]
10. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484 [TBL] [Abstract][Full Text] [Related]
11. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS). Ploner F; Lamm W; Schur S; Eisterer W; Kühr T; Lindorfer A; Tinchon C; Köstler WJ; Szkandera J; Brodowicz T J Cancer Res Clin Oncol; 2013 Aug; 139(8):1337-42. PubMed ID: 23666164 [TBL] [Abstract][Full Text] [Related]
12. A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. Bui-Nguyen B; Butrynski JE; Penel N; Blay JY; Isambert N; Milhem M; Kerst JM; Reyners AK; Litière S; Marréaud S; Collin F; van der Graaf WT; Eur J Cancer; 2015 Jul; 51(10):1312-20. PubMed ID: 25912752 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Kawai A; Araki N; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Tanase T; Hasegawa T; Takahashi S Lancet Oncol; 2015 Apr; 16(4):406-16. PubMed ID: 25795406 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. Kobayashi H; Iwata S; Wakamatsu T; Hayakawa K; Yonemoto T; Wasa J; Oka H; Ueda T; Tanaka S Cancer; 2020 Mar; 126(6):1253-1263. PubMed ID: 31825533 [TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065 [TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Forouzesh B; Hidalgo M; Chu Q; Mita A; Mita M; Schwartz G; Jimeno J; Gómez J; Alfaro V; Lebedinsky C; Zintl P; Rowinsky EK Clin Cancer Res; 2009 May; 15(10):3591-9. PubMed ID: 19417019 [TBL] [Abstract][Full Text] [Related]
19. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F; Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]